## STANDARD TREATMENT WORKFLOW (STW) Hypothyroidism

### Anil Bhansali<sup>1</sup>, Eesh Bhatia<sup>2</sup>, B Ganpathi<sup>3</sup>, Maj Gen Narendra Kotwal<sup>4</sup>, Rajesh Rajput<sup>5</sup>, Ravinder Goswami<sup>6</sup>, Subhankar Choudhary<sup>7</sup>, V Mohan<sup>8</sup>

<sup>1</sup>Postgraduate Institute of Medical Education and Research, Chandigarh; <sup>2</sup>Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow; <sup>3</sup>St John's Medical College Hospital, Bengaluru; <sup>4</sup>Army Hospital Research and Referral, New Delhi; <sup>5</sup>Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak; <sup>6</sup>All India Institute of Medical Sciences, New Delhi; <sup>7</sup>Institute of Post-Graduate Medical Education and Research, Kolkata; <sup>8</sup>Dr. Mohan's Diabetes Specialities Centre, Chennai

#### **CORRESPONDING AUTHOR**

Dr. Anil Bhansali, Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh

Email: anilbhansali endocrine@rediffmail.com

#### CITATION

Bhansali A, Bhatia E, Ganpathi B, Kotwal N, Rajput R, Goswami R, Choudhary S, Mohan V. Hypothyroidism. Journal of the Epidemiology Foundation of India. 2024;2(1Suppl):S115-S116. DOI: <u>https://doi.org/10.56450/JEFI.2024.v2i1Suppl.058</u>

*This work is licensed under a Creative Commons Attribution 4.0 International License.* ©*The Author(s). 2024 Open Access* 

#### DISCLAIMER

This article/STW, was originally published by Indian Council of Medical Research (ICMR) under Standard Treatment Workflow. The reprinting of this article in Journal of the Epidemiology Foundation of India (JEFI) is done with the permission of ICMR. The content of this article is presented as it was published, with no modifications or alterations. The views and opinions expressed in the article are those of the authors and do not necessarily reflect the official policy or position of JEFI or its editorial board. This initiative of JEFI to reprint STW is to disseminate these workflows among Health Care Professionals for wider adoption and guiding path for Patient Care.





# Standard Treatment Workflow (STW) HYPOTHYROIDISM

ICD-10-E03.9

WHEN TO SUSPECT HYPOTHYROIDISM ON CLINICAL GROUNDS?				
Primary hypothyroidism	Congenital hypothyroidism	Central (Secondary) hypothyroidism		
Symptoms Fatigue / Weight gain with poor appetite / Dry skin and cold intolerance / Hair loss / Constipation / Hoarseness of voice / Dyspnea / Muscle weakness and cramps / Menorrhagia (later oligomenorrhea or amenorrhea) / Infertility / Difficulty concentration and poor memory / Paraesthesia / Impaired hearing Signs Dry coarse skin / Cool peripheral extremities / Puffy face, hands and feet (myxoedema) / Diffuse alopecia / Goitre / Bradycardia / Peripheral Oedema / Delayed tendon reflex relaxation / Carpel tunnel syndrome / Serous cavity effusions	New born screening (usually asymptomatic)Prolonged icterus / Edema of the eyelids, hands, and feet / Hypotonia / Inactivity / Gestation > 42 wk / Birth weight > 4 kg / Poor feeding / Hypothermia / Abdominal distention / Open posterior fontanelle (> 5 mm)	Mild-moderate symptoms of hypothyroidism / Signs and symptoms of other pituitary deficits / Manifestations of concomitant hypothalamic pituitary disease Clinical manifestation are less pronounced in secondary hypothyroidism as compared to primary hypothyroidism as there may be multiple pituitary hormone deficiencies which can mask the features of hypothyroidism		



July/ 2022



#### **Standard Treatment Workflow (STW) HYPOTHYROIDISM**

ICD-10-E03.9

Primary hypothyroidism		Congenital hypothyroidism		Central (Se	Central (Secondary) hypothyroidic	
Primary hypothyroidism Symptoms		Congenital hypothyroidism		Central (Secondary) hypothyroidise Mild-moderate symptoms of		
Fatigue / Weight gain with poor appetit	e / Dry skin		matic)Prolonged icterus	100	dism / Signs and symptom:	
and cold intolerance / Hair loss / Constipation /			/ Edema of the eyelids, hands,		of other pituitary deficits /	
Hoarseness of voice / Dyspnea / Muscle weakness and cramps / Menorrhagia (later oligomenorrhea or		and feet / Hypotonia / Inactivity /		Manifestations of concomitant		
amenorrhea) / Infertility / Difficulty concentration		Gestation > 42 wk / Birth weight		hypothalan	nic pituitary disease Clinica	
and poor memory / Paraesthesia / Impa	ired	> 4 kg / Poor feeding /		manifestation are less pronounced in		
hearing <b>Signs</b>		Hypothermia / Abdominal		secondary	hypothyroidism as	
Dry coarse skin / Cool peripheral extremities / Puffy		distention / Open posterior		and the second	to primary hypothyroidism	
face, hands and feet (myxoedema) / Diffuse		fontanelle (> 5 mm)			ay be multiple pituitary	
alopecia / Goitre / Bradycardia / Peripheral Oedema Delayed tendon reflex relaxation / Carpel tunnel				hormone deficiencies which can mask the features of hypothyroidism		
syndrome / Serous cavity effusions				the feature	s of hypothyroidism	
Bill	ewicz scori	ng for dia	gnosis of Hypothyroi	dism		
	ore if present		Physical signs		Score if present	
Hearing impairment	1		Slow movement		1	
Diminished sweating	1		Periorbital puffiness		1	
Constipation	1		Delayed ankle reflex		1	
Paraesthesia	1		Coarse skin		1	
Haorseness	1		Cold skin		1	
Weight increase	1		Add 1 point for wo		than 55 years	
Dry skin	1		Total score:12			
lypothyroid ≥6 points			diate 3-5 points	Euthyroid ≤2 points		
			L SUSPICION OF HYPO			
Primary hypothyroidism	c	ongenital I	nypothyroidism	Central (Se	condary) hypothyroidism	
<b>ests to be ordered</b> SH	Tests t TSH	o be orde	ered after 72 hours	Tests to be	ordered	
T4 or Total T4	FT4 or T	F5H FT4 or T4 USG neck, nuclear imaging (Not a must, Do not delay treatment)		TSH Other pituitary profile Imaging of sella Interpretation		
PO antibodies (if available) nterpretation						
Overt hypothyroidism - TSH elevated wi	th Interp				rmal or low with low FT4 or	
ow FT4 or T4 levels Subclinical hypothyroidism - TSH elevat			80 mU/ L; T4 < 10th ry - TSH > 9 mU/L; FT4	T4 levels		
vith normal FT4 or T4 levels	< 0.6 ng		IY - 13H > 9 110/L, F14			
		INITIATIN	G THERAPY			
Primary hypothyroidism		Congenital hypothyroidism		Central (Secondary) hypothyroidism		
Levothyroxine 1.6 to 1.8 mcg per kg per day Single dose, fasting status, no calorie intake for 1 hour thereafter Titrate based on TSH levels Elderly and			roxine therapy 10 to 15			
			dosing Given with breast milk in treating co existing adre			
CAD patients: Start with 12.5–25 mcg/d	with 12.5 -	and the second second second	ed form Titrate based on	insufficient	cy with Hydrocortisone	
25mcg/d incremental dose every 3–4 wk Consider treating subclinical hypothyroidism in presence of -		FT4 levels and TSH initially, later			nt as there is risk of ng adrenal crisis,	
Large goitre / Positive TPO antibody / ASCVD / Heart		based on TSH levels		Titrate based on FT4 or T4 levels		
failure / Dyslipidemia / Infertility / Depre refractory anaemia / personal or family						
autoimmune disease						
	HOW SHOUL	D THE PAT	IENT BE FOLLOWED UP	;		
Primary hypothyroidism			ypothyroidism	Central (Se	econdary) hypothyroidism	
Titrate based on TSH levels		based on	FT4 or T4 levels and	A CONTRACTOR OF A CONTRACTOR A	ased on FT4 or T4	
Farget TSH	TSH Titrate bi	ased on ET	or T/ levels and TCU	levels		
<ul> <li>Young patient's 1–2.5 mU/L</li> <li>Middle-aged patients 1.5–3</li> </ul>	the second s	Titrate based on FT4 or T4 levels and TSH Target T4: 10 to 16 mcg/dl		• Target T4 or FT4 Young people -		
Elderly patients	-	Target FT4: 10 to 16 mcg/dl Target FT4: 1.4 to 2.3 ng/dl		upper half of normal range		
< 60 y: > 4.5 mU/L		Target TSH: 0.5 to 2 mU/L			nid normal range	
∘ 60–70 y: > 6.0 mU/L		Initial follow up at 2 and 4 weeks			to 6 months initially, once	
• 70–80 y: > 7.0 to 8.0 mU/L		very 1 to 2 months in first 6 months		and the second s	e is achieved, annual	
Once in 3 to 6 months initially, once		ery 3 to 4 months from 6 months to 3		follow up		
stable dose is achieved appual follow	<ul> <li>A second sec second second sec</li></ul>	ry 6 to 12 months till growth is complete				
stable dose is achieved, annual follow u	Every or					
stable dose is achieved, annual follow u	Liciyot	ABBRE	VIATIONS			
stable dose is achieved, annual follow u			viations oid peroxidase	US	G: Ultrasound sonography	
		TPO: Thyr		Us	GC: Ultrasound sonography	
ASCVD: Atherosclerotic cardiovascula		TPO: Thyr	oid peroxidase pid-stimulating hormone	US	G: Ultrasound sonography	

This STW has been prepared by national experts of India with feasibility considerations for various levels of healthcare system in the country. These broad guidelines are advisory, and are based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on hig/her specific condition, as decided by the treating physician. There will be no indemnity for direct or indirect consequences. Kindly visit the website of DHR for more information. (stwiemr.org.in) for more information. @Department of Health Research, Ministry of Health & Family Welfare, Government of India.